

All information is as of 01/22/2018 and is subject to change.

Equity	CUSIPs		Fee CUSIPs		Ticker	Term
Target Strategy Portfolios — U.S. Equity						
Dow® Target 10, January 2018	30305Y	351 (c) 369 (r)	30305Y	377 (c) 385 (r)	FWANRX	13 Month
Dow® Target 5, 1st Qtr 2018	30305X	486 (c) 494 (r)	30305X	502 (c) 510 (r)	FHNUSX	15 Month
Dow® Target Dividend, 1st Qtr 2018	30305X	528 (c) 536 (r)	30305X	544 (c) 551 (r)	FTQLMX	15 Month
S&P Dividend Aristocrats Target 25, 1st Qtr 2018	30305X	601 (c) 619 (r)	30305X	627 (c) 635 (r)	FIDZVX	15 Month
S&P Target 24, 1st Qtr 2018	30305X	643 (c) 650 (r)	30305X	668 (c) 676 (r)	FOTSPX	15 Month
S&P Target SMid 60, 1st Qtr 2018	30305Y	104 (c) 112 (r)	30305Y	120 (c) 138 (r)	FPRNWX	15 Month
Target Diversified Dividend, 1st Qtr 2018	30305X	684 (c) 692 (r)	30305X	700 (c) 718 (r)	FTYPMX	15 Month
Target Growth, 1st Qtr 2018	30305Y	195 (c) 203 (r)	30305Y	211 (c) 229 (r)	FWDTRX	15 Month
Target High Quality Dividend, 1st Qtr 2018	30305X	445 (c) 452 (r)	30305X	460 (c) 478 (r)	FKPMYX	15 Month
Value Line® Target 25, 1st Qtr 2018	30305X	809 (c) 817 (r)	30305X	825 (c) 833 (r)	FQCBGX	15 Month
Value Line® Target Safety 30, 1st Qtr 2018	30306F	344 (c) 351 (r)	30306F	369 (c) 377 (r)	FLNZIX	15 Month
Target Strategy Portfolios — Foreign/Global						
European Target High Quality Dividend, 1st Qtr 2018	30305X	361 (c) 379 (r)	30305X	387 (c) 395 (r)	FNKDTX	15 Month
Global Target 15, 1st Qtr 2018	30305X	569 (c) 577 (r)	30305X	585 (c) 593 (r)	FKCPEX	15 Month
Target Global Dividend Leaders, 1st Qtr 2018	30305X	767 (c) 775 (r)	30305X	783 (c) 791 (r)	FTYHMX	15 Month
Target Strategy Portfolios — Multi-Strategy						
Target Diversified Global Allocation, 1st Qtr 2018	30305Y	435 (c) 443 (r)	30305Y	450 (c) 468 (r)	FEBTHX	15 Month
Target Dividend Blend, 1st Qtr 2018	30305X	403 (c) 411 (r)	30305X	429 (c) 437 (r)	FVGRCX	15 Month
Target Double Play, 1st Qtr 2018	30305X	726 (c) 734 (r)	30305X	742 (c) 759 (r)	FGSITX	15 Month
Target Focus Four, 1st Qtr 2018	30305Y	146 (c) 153 (r)	30305Y	161 (c) 179 (r)	FJNDHX	15 Month
Target Triad, 1st Qtr 2018	30305Y	237 (c) 245 (r)	30305Y	252 (c) 260 (r)	FGMULX	15 Month
Target VIP, 1st Qtr 2018	30305Y	278 (c) 286 (r)	30305Y	294 (c) 302 (r)	FKRTLX	15 Month
Sector/Industry Portfolios						
Aerospace & Defense, 19	30306F	104 (c) 112 (r)	30306F	120 (c) 138 (r)	FNIAPX	2 Year
AI & Robotics Opportunity, 2	30306F	724 (c) 732 (r)	30306F	740 (c) 757 (r)	FAMCHX	15 Month
Banking Opportunity, 28	30305W	660 (c) 678 (r)	30305W	686 (c) 694 (r)	FEIOLX	15 Month
Biotechnology, 39	30306A	469 (c) 477 (r)	30306A	485 (c) 493 (r)	FWLNXX	2 Year
Cloud Computing, 19	30305W	587 (c) 595 (r)	30305W	603 (c) 611 (r)	FCHACX	2 Year
Defensive Equity, 43	30305W	629 (c) 637 (r)	30305W	645 (c) 652 (r)	FQNBXX	2 Year
E-Commerce Opportunity, 2	30306F	641 (c) 658 (r)	30306F	666 (c) 674 (r)	FZBTDX	15 Month
Energy Select, 66	30306A	105 (c) 113 (r)	30306A	121 (c) 139 (r)	FTUNMX	2 Year
Financials Select, 62	30305V	787 (c) 795 (r)	30305V	803 (c) 811 (r)	FSAQNX	2 Year
Health Care Opportunity, 2	30305T	766 (c) 774 (r)	30305T	782 (c) 790 (r)	FBRPTX	15 Month
Health Care Select, 48	30305V	225 (c) 233 (r)	30305V	241 (c) 258 (r)	FEHCTX	2 Year
Homebuilders Recovery Select, 18	30306G	268 (c) 276 (r)	30306G	284 (c) 292 (r)	FOHYGX	2 Year
Richard Bernstein Advisors Tactical Series, American Industrial Renaissance®, 2017-4	30306F	260 (c) 278 (r)	30306F	286 (c) 294 (r)	FDHTOX	2 Year
Technology Opportunity, 3	30306G	342 (c) 359 (r)	30306G	367 (c) 375 (r)	FEDJNX	15 Month
Technology Select, 67	30305V	308 (c) 316 (r)	30305V	324 (c) 332 (r)	FDROXX	2 Year
U.S. Energy Independence, 17	30306A	709 (c) 717 (r)	30306A	725 (c) 733 (r)	FMQYLX	2 Year
U.S. Infrastructure, 13	30305Y	708 (c) 716 (r)	30305Y	724 (c) 732 (r)	FLJNWX	2 Year
Utilities Select, 45	30305V	183 (c) 191 (r)	30305V	209 (c) 217 (r)	FUOPWX	2 Year
Water Utility & Infrastructure Select, 48	30306A	741 (c) 758 (r)	30306A	766 (c) 774 (r)	FTRMIX	2 Year
Foreign/Global Portfolios						
Emerging Markets Strength, 39	30306X	303 (c) 311 (r)	30306X	329 (c) 337 (r)	FKEHTX	2 Year
International Capital Strength Opportunity, 3	30306D	745 (c) 752 (r)	30306D	760 (c) 778 (r)	FJUNXX	15 Month
International Capital Strength, 36	30305U	102 (c) 110 (r)	30305U	128 (c) 136 (r)	FWEQNX	2 Year
Strategic International Opportunity, 3	30306F	567 (c) 575 (r)	30306F	583 (c) 591 (r)	FNIYEX	15 Month

All information is as of 01/22/2018 and is subject to change.

Equity	CUSIPs		Fee CUSIPs		Ticker	Term
Theme/Specialty Portfolios						
American Agenda, 3	30304N	349 (c) 356 (r)	30304N	364 (c) 372 (r)	FDYIRX	2 Year
Capital Strength Opportunity, 3	30305Y	625 (c) 633 (r)	30305Y	641 (c) 658 (r)	FRIVDX	15 Month
Capital Strength, 40	30305U	508 (c) 516 (r)	30305U	524 (c) 532 (r)	FHDIRX	2 Year
Content Leaders, 7	30305W	223 (c) 231 (r)	30305W	249 (c) 256 (r)	FAQSYX	15 Month
Corporate Tax Reform, 4	30305W	108 (c) 116 (r)	30305W	124 (c) 132 (r)	FAPRTX	2 Year
Cybersecurity, 10	30305W	702 (c) 710 (r)	30305W	728 (c) 736 (r)	FPNGTX	2 Year
Cyclical Strength, 20	30306A	667 (c) 675 (r)	30306A	683 (c) 691 (r)	FTBSMX	2 Year
Dorsey Wright Relative Strength Top 50, 29	30306A	501 (c) 519 (r)	30306A	527 (c) 535 (r)	FBMLJX	15 Month
Dow Jones Global Titans, 23	30306F	484 (c) 492 (r)	30306F	500 (c) 518 (r)	FRGNBX	2 Year
Election Portfolio, 2016 Series 5	30304M	382 (c) 390 (r)	30304M	408 (c) 416 (r)	FODRCX	2 Year
ESG Impact Opportunity, 1	30305V	621 (c) 639 (r)	30305V	647 (c) 654 (r)	FYDUPX	15 Month
Innovative Technology, 17	30306F	302 (c) 310 (r)	30306F	328 (c) 336 (r)	FMBWUX	2 Year
Low Volatility, 10	30306F	229 (c) 237 (r)	30306F	245 (c) 252 (r)	FLKVRX	15 Month
Market Strength Allocation Opportunity, 3	30306A	584 (c) 592 (r)	30306A	600 (c) 618 (r)	FLRGNX	15 Month
Market Strength Allocation Select, 29	30305U	540 (c) 557 (r)	30305U	565 (c) 573 (r)	FZPYOX	2 Year
Mega-Cap, 47	30306F	187 (c) 195 (r)	30306F	203 (c) 211 (r)	FCDIGX	2 Year
Nasdaq Factor Dogs Opportunity, 1	30302T	462 (c) 470 (r)	30302T	488 (c) 496 (r)	FNHBLX	15 Month
Sabrient Baker's Dozen, January 2018	30306G	508 (c) 516 (r)	30306G	524 (c) 532 (r)	FCVZLX	13 Month
Sabrient Defensive Equity, 14	30305W	504 (c) 512 (r)	30305W	520 (c) 538 (r)	FJLZRX	15 Month
Sabrient Rising Rate, 6	30304V	143 (c) 150 (r)	30304V	168 (c) 176 (r)	FQJZMX	2 Year
Sabrient Small Cap Growth, 17	30306D	224 (c) 232 (r)	30306D	240 (c) 257 (r)	FMLLYX	15 Month
SMid Capital Strength Opportunity, 3	30306D	786 (c) 794 (r)	30306D	802 (c) 810 (r)	FRTOVX	15 Month
SMid Capital Strength, 36	30305U	144 (c) 151 (r)	30305U	169 (c) 177 (r)	FJBZLX	2 Year
Tactical Alpha, 15	30306D	588 (c) 596 (r)	30306D	604 (c) 612 (r)	FLCRAX	15 Month
U.S. Revenue, 11	30306F	609 (c) 617 (r)	30306F	625 (c) 633 (r)	FTLKPX	2 Year
Asset Allocation						
40/60 Strategic Allocation, 1st Qtr 2018	30306D	307 (c) 315 (r)	30306D	323 (c) 331 (r)	FBMDUX	15 Month
60/40 Strategic Allocation, 1st Qtr 2018	30306D	422 (c) 430 (r)	30306D	448 (c) 455 (r)	FRZMJX	15 Month
75/25 Strategic Allocation, 1st Qtr 2018	30306D	463 (c) 471 (r)	30306D	489 (c) 497 (r)	FSTVLX	15 Month
Diversified Equity Strategic Allocation, 1st Qtr 2018	30305Y	393 (c) 401 (r)	30305Y	419 (c) 427 (r)	FLNIAX	15 Month
Diversified Fixed Income ETF, 33	30306D	265 (c) 273 (r)	30306D	281 (c) 299 (r)	FEAOUX	15 Month
ETF Growth and Income, January 2018	30306G	102 (c) 110 (r)	30306G	128 (c) 136 (r)	FNLDRX	15 Month
First Trust® ETF Allocation, 23	30306D	349 (c) 356 (r)	30306D	364 (c) 372 (r)	FEWKAX	2 Year
Income						
Equity Income Portfolios						
Brookmont Equity Dividend, 14	30306F	385 (c) 393 (r)	30306F	401 (c) 419 (r)	FGPACX	15 Month
Covered Call Select Closed-End, 64	30306F	682 (c) 690 (r)	30306F	708 (c) 716 (r)	FGSBEX	2 Year
Deep Value Dividend Opportunity, 3	30306X	543 (c) 550 (r)	30306X	568 (c) 576 (r)	FPYOBX	15 Month
Deep Value Dividend, 17	30305V	464 (c) 472 (r)	30305V	480 (c) 498 (r)	FKCLHX	2 Year
Diversified Income & Growth, Winter 2017	30305B	583 (c) 591 (r)	30305B	609 (c) 617 (r)	FBQLJX	5 Year
Dividend & Income Select Closed-End, 63	30306Y	186 (c) 194 (r)	30306Y	202 (c) 210 (r)	FGWLEX	2 Year
Dividend Edge, 9	30305Y	849 (c) 856 (r)	30305Y	864 (c) 872 (r)	FSRNHX	15 Month
Dividend Growth, 20	30305Y	542 (c) 559 (r)	30305Y	567 (c) 575 (r)	FKWSRX	5 Year
Dividend Strength Opportunity, 3	30305W	785 (c) 793 (r)	30305W	801 (c) 819 (r)	FPULDY	15 Month
Dividend Strength, 38	30305U	466 (c) 474 (r)	30305U	482 (c) 490 (r)	FVANBX	2 Year
Dorsey Wright Relative Strength Dividend, 29	30306D	703 (c) 711 (r)	30306D	729 (c) 737 (r)	FDKRGX	15 Month
Equity Closed-End, 47	30306D	109 (c) 117 (r)	30306D	125 (c) 133 (r)	FSBVPX	2 Year
Equity Income Opportunity, 2	30305U	581 (c) 599 (r)	30305U	607 (c) 615 (r)	FKBJNX	15 Month

All information is as of 01/22/2018 and is subject to change.

Income	CUSIPs		Fee CUSIPs		Ticker	Term
<u>Equity Income Portfolios Continued</u>						
Equity Income Select, 55	30305V	506 (c) 514 (r)	30305V	522 (c) 530 (r)	FJBLTX	2 Year
Equity Income, 58	30305W	140 (c) 157 (r)	30305W	165 (c) 173 (r)	FQNCGX	5 Year
European Deep Value Dividend, 17	30305U	227 (c) 235 (r)	30305U	243 (c) 250 (r)	FWEUTX	2 Year
Global Deep Value Dividend, 17	30306D	661 (c) 679 (r)	30306D	687 (c) 695 (r)	FUZVCX	15 Month
Global Dividend, 53	30305V	662 (c) 670 (r)	30305V	688 (c) 696 (r)	FLEBTX	2 Year
Global Equity Income Closed-End, 57	30305W	348 (c) 355 (r)	30305W	363 (c) 371 (r)	FZRNCX	2 Year
High Dividend Equity Allocation, 26	30306A	188 (c) 196 (r)	30306A	204 (c) 212 (r)	FLZTYX	2 Year
High Dividend Equity Opportunity, 3	30306X	667 (c) 675 (r)	30306X	683 (c) 691 (r)	FYIHOX	15 Month
High Dividend Equity, 34	30305V	266 (c) 274 (r)	30305V	282 (c) 290 (r)	FHTNUX	2 Year
Income Dividend Equity Allocation (IDEA), 15	30306X	584 (c) 592 (r)	30306X	600 (c) 618 (r)	FQMWLX	2 Year
International High Dividend Equity, 32	30306F	146 (c) 153 (r)	30306F	161 (c) 179 (r)	FSOILX	2 Year
Nasdaq® Dividend Achievers 25, 11	30306F	526 (c) 534 (r)	30306F	542 (c) 559 (r)	FDAERX	2 Year
REIT Growth & Income Select, 44	30306A	824 (c) 832 (r)	30306A	840 (c) 857 (r)	FBRTMX	2 Year
Richard Bernstein Advisors Global Dividend Kings®, 25	30306G	185 (c) 193 (r)	30306G	201 (c) 219 (r)	FKRQPX	2 Year
Richard Bernstein Advisors Quality Income, 27	30305T	725 (c) 733 (r)	30305T	741 (c) 758 (r)	FKESVX	15 Month
Sabrient Dividend, 21	30305V	100 (c) 118 (r)	30305V	126 (c) 134 (r)	FSNTVX	2 Year
Select DSIP, 1st Qtr 2018	30306D	380 (c) 398 (r)	30306D	406 (c) 414 (r)	FTZHAX	15 Month
SMid High Dividend, 28	30305W	306 (c) 314 (r)	30305W	322 (c) 330 (r)	FOEAPX	2 Year
Strategic Dividend Select, 31	30306A	543 (c) 550 (r)	30306A	568 (c) 576 (r)	FYARHX	2 Year
Technology Dividend, 24	30305U	623 (c) 631 (r)	30305U	649 (c) 656 (r)	FGRDIX	2 Year
U.S. Equity Closed-End Portfolio, 26	30306X	469 (c) 477 (r)	30306X	485 (c) 493 (r)	FPNCMX	2 Year
<u>Taxable Income Portfolios</u>						
Global Bond Income Closed-End, 27	30305Y	476 (c) 484 (r)	30305Y	492 (c) 500 (r)	FYTDBX	2 Year
High-Yield Income Closed-End, 80	30306X	626 (c) 634 (r)	30306X	642 (c) 659 (r)	FNEVJX	2 Year
Investment Grade Select Closed-End & ETF, 4	30304L	780 (c) 798 (r)	30304L	806 (c) 814 (r)	FSLKTX	2 Year
Limited Duration Fixed Income ETF, 22	30305V	381 (c) 399 (r)	30305V	407 (c) 415 (r)	FKIYLY	2 Year
Preferred Income Opportunity, 7	30305U	300 (c) 318 (r)	30305U	326 (c) 334 (r)	FRAYDX	15 Month
Preferred Income, 93	30306X	105 (c) 113 (r)	30306X	121 (c) 139 (r)	FYAPMX	2 Year
Senior Loan & Limited Duration Closed-End, 78	30306D	182 (c) 190 (r)	30306D	208 (c) 216 (r)	FWAELX	2 Year
Senior Loan & Limited Duration Opportunities Closed-End, 51	30305Y	583 (c) 591 (r)	30305Y	609 (c) 617 (r)	FQMRXL	15 Month
Senior Loan Closed-End and ETF, 20	30305W	546 (c) 553 (r)	30305W	561 (c) 579 (r)	FNOYEX	2 Year
Senior Loan Select Closed-End, 29	30305W	744 (c) 751 (r)	30305W	769 (c) 777 (r)	FRGZBX	2 Year
Stonebridge Preferred Income, 16	30306D	141 (c) 158 (r)	30306D	166 (c) 174 (r)	FPCWLX	2 Year
Strategic Income Closed-End, 65	30305X	288 (c) 296 (r)	30305X	304 (c) 312 (r)	FQBDHX	2 Year
Tactical Income Opportunity, 3	30305X	163 (c) 171 (r)	30305X	189 (c) 197 (r)	FDWHSX	15 Month
Tactical Income, 50	30305T	584 (c) 592 (r)	30305T	600 (c) 618 (r)	FYMPWX	2 Year
<u>Tax-Free Income Portfolios</u>						
California Municipal Income Select Closed-End, 64	30306A	261 (c) 279 (r)	30306A	287 (c) 295 (r)	FVXGJX	2 Year
Municipal Advantage Closed-End and ETF, 45	30305X	106 (c) 114 (r)	30305X	122 (c) 130 (r)	FSMYTX	2 Year
Municipal Income Closed-End, 72	30305V	340 (c) 357 (r)	30305V	365 (c) 373 (r)	FEQBNX	5 Year
Municipal Income Opportunities Closed-End, 47	30306A	386 (c) 394 (r)	30306A	402 (c) 410 (r)	FWLBGX	15 Month
Municipal Income Select, Closed-End, 92	30306Y	145 (c) 152 (r)	30306Y	160 (c) 178 (r)	FGEKLY	2 Year
New Jersey Municipal Income Select Closed-End, 58	30305W	827 (c) 835 (r)	30305W	843 (c) 850 (r)	FYZKJX	2 Year
New York Municipal Income Select Closed-End, 45	30306A	147 (c) 154 (r)	30306A	162 (c) 170 (r)	FVLQBX	2 Year
Tax-Advantaged Municipal Closed-End, 53	30306D	620 (c) 638 (r)	30306D	646 (c) 653 (r)	FJYBZX	2 Year
<u>Hybrid Portfolios</u>						
Alternative Income, 26	30306D	547 (c) 554 (r)	30306D	562 (c) 570 (r)	FGNLEX	2 Year
Balanced Income Equity and ETF, 29	30305U	789 (c) 797 (r)	30305U	805 (c) 813 (r)	FIAUVX	2 Year
Balanced Income Opportunity, 3	30306D	505 (c) 513 (r)	30306D	521 (c) 539 (r)	FJZBMX	15 Month

All information is as of 01/22/2018 and is subject to change.

Income	CUSIPs		Fee CUSIPs		Ticker	Term
Hybrid Portfolios Continued						
Balanced Income Select, 73	30305X	247 (c) 254 (r)	30305X	262 (c) 270 (r)	FBELPX	2 Year
Balanced Income, 60	30306X	501 (c) 519 (r)	30306X	527 (c) 535 (r)	FKQYZX	5 Year
Capital Strength Buy-Write, 36	30305Y	823 (c)	30305Y	831 (c)	FAHCEX	13 Month
Core Three Closed-End Allocation, 33	30306X	220 (c) 238 (r)	30306X	246 (c) 253 (r)	FZHSVX	2 Year
Diversified High Income Closed-End, 30	30305Y	666 (c) 674 (r)	30305Y	682 (c) 690 (r)	FQBCNX	2 Year
Income Allocation Closed-End, 1st Qtr 2018	30305Y	310 (c) 328 (r)	30305Y	336 (c) 344 (r)	FNQRDX	15 Month
Inflation Hedge, 36	30306G	466 (c) 474 (r)	30306G	482 (c) 490 (r)	FRYBWX	2 Year
Interest Rate Hedge and ETF, 18	30305B	187 (c) 195 (r)	30305B	203 (c) 211 (r)	FNEVDX	2 Year
Interest Rate Hedge Opportunity, 3	30305W	462 (c) 470 (r)	30305W	488 (c) 496 (r)	FLARVX	15 Month
Interest Rate Hedge, 116	30307A	708 (c) 716 (r)	30307A	724 (c) 732 (r)	FCLBNX	2 Year
MLP Closed-End Fund and Energy, 58	30306G	227 (c) 235 (r)	30306G	243 (c) 250 (r)	FQWKBX	2 Year
MLP Closed-End, 19	30306G	425 (c) 433 (r)	30306G	441 (c) 458 (r)	FWLARX	2 Year
Multi-Sector Income, 38	30305V	746 (c) 753 (r)	30305V	761 (c) 779 (r)	FBLHWX	15 Month
Municipal Income and Dividend Growers, 12	30304L	822 (c) 830 (r)	30304L	848 (c) 855 (r)	FUDZTX	2 Year
Senior Loan and Dividend Growers, 16	30305T	626 (c) 634 (r)	30305T	642 (c) 659 (r)	FSYKCX	2 Year
Strategic Income Advantage Opportunity, Closed-End, 4	30306F	427 (c) 435 (r)	30306F	443 (c) 450 (r)	FDWGSX	15 Month
Strategic Income Advantage Select Closed-End, 72	30306Y	343 (c) 350 (r)	30306Y	368 (c) 376 (r)	FRTBGX	2 Year
Strategic Income Select Closed-End, 32	30306A	220 (c) 238 (r)	30306A	246 (c) 253 (r)	FCREBX	2 Year

Unit Investment Trust Features

A unit investment trust (UIT) is a pooled investment vehicle in which a fixed portfolio of stocks, bonds or other securities is selected by the sponsor, deposited into the trust, and held for a predetermined period of time. Investors purchase units of a trust, which represent an undivided ownership interest in the assets contained in the trust. A UIT follows a buy and hold strategy and investors should consider their ability to hold a trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan. Units of a trust can be liquidated daily at the redemption price, which may be more or less than the original purchase price.

Risk Considerations

There are risks involved with investing in UITs, including the potential loss of money. There is no assurance an unmanaged unit investment trust will achieve its investment objective(s). Please be aware that each UIT listed is subject to various risks which, depending on the investment objective, may include risks such as concentration, sector, interest rate, credit, fixed-income or equity investing, options, high-yield securities, commodities, and foreign and emerging markets. In addition, the value of the securities held by a trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers. For a complete description of relative risks for a specific trust please obtain and carefully read the prospectus.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.

You should consider a trust's investment objective, risks, and charges and expenses carefully before investing. Contact your financial advisor or call First Trust Portfolios L.P. at 1-800-621-1675 to request a prospectus, which contains this and other information about a trust. Read it carefully before you invest.

Nasdaq[®] and NASDAQ US Broad Dividend Achievers Index[™] are registered trademarks of Nasdaq, Inc. (which with its affiliates are the Corporations) and are licensed for use by First Trust Portfolios L.P. The Nasdaq[®] Dividend Achievers 25 portfolio has not been passed on by the Corporations as to its legality or suitability. The portfolio is not issued, endorsed, sold, or promoted by the Corporations. **THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE PORTFOLIO.**

"S&P", "S&P MidCap 400", "S&P SmallCap 600", "S&P 500" and "Standard & Poor's" are trademarks of The McGraw-Hill Companies, Inc. and have been licensed for use by First Trust Portfolios L.P. The S&P Target 24 and S&P Target SMid 60 Portfolios are not sponsored, endorsed, sold, or promoted by Standard & Poor's and Standard & Poor's makes no representation regarding the advisability of investing in such products.

Value Line, The Value Line Investment Survey, and Timeliness are trademarks or registered trademarks of Value Line, Inc. and/or its affiliates ("Value Line") that have been licensed to First Trust Portfolios L.P. and/or First Trust Advisors L.P. The Target Double Play, Target Focus Four, Target VIP and Value Line[®] Target 25 Portfolios are not sponsored, endorsed, sold or promoted by Value Line. Value Line makes no representation regarding the advisability of investing in a Trust.

The "Dow Jones Industrial Average" is a product of S&P Dow Jones Indices LLC ("SPDJI"), and has been licensed for use by First Trust Advisors L.P. Standard & Poor's[®] and S&P[®] are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); DJIA[®], The Dow[®], Dow Jones[®], and Dow Jones Industrial Average are trademarks of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by First Trust Advisors L.P. The Dow[®] Target 5, The Dow[®] Target 10 and The Dow[®] Target Dividend Portfolios, are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such product.

The Dow Jones Global Titans 50[™] Index is a product of S&P Dow Jones Indices LLC or its affiliates ("SPDJI") and Global Titans[®] is a registered trademark of SPDJI. Both have been licensed for use by First Trust Portfolios L.P. Standard & Poor's[®] and S&P[®] are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones[®] is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by First Trust Portfolios L.P. The Dow Jones Global Titans Portfolio is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the Dow Jones Global Titans 50[™] Index.